American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
PURPOSE:Because toxicities associated with chemotherapy and radiotherapy canadversely affect short- and long-term patient quality of life, can limitthe dose and duration of treatment, and may be life-threatening, specificagents designed to ameliorate or eliminate certain chemotherapy andradiotherapy toxicities have been developed. Variability in interpretationof the available data pertaining to the efficacy of the three United StatesFood and Drug Administration–approved agents that have potentialchemotherapy- and radiotherapy-protectant activity—dexrazoxane,mesna, and amifostine—and questions about the role of theseprotectant agents in cancer care led to concern about the appropriate useof these agents. The American Society of Clinical Oncology sought toestablish evidence-based, clinical practice guidelines for the use ofdexrazoxane, mesna, and amifostine in patients who are not enrolled onclinical treatment trials. METHODS: A multidisciplinary Expert Panelreviewed the clinical data regarding the activity of dexrazoxane, mesna,and amifostine. A computerized literature search was performed usingMEDLINE. In addition to reports collected by individual Panel members, allarticles published in the English-speaking literature from June 1997through December 1998 were collected for review by the Panel chairpersons,and appropriate articles were distributed to the entire Panel for review.Guidelines for use, levels of evidence, and grades of recommendation werereviewed and approved by the Panel. Outcomes considered in evaluating thebenefit of a chemotherapy- or radiotherapy-protectant agent includedamelioration of short- and long-term chemotherapy- or radiotherapy-relatedtoxicities, risk of tumor protection by the agent, toxicity of theprotectant agent itself, quality of life, and economic impact. To theextent that these data were available, the Panel placed the greatest valueon lesser toxicity that did not carry a concomitant risk of tumorprotection. RESULTS AND CONCLUSION: Mesna: (1) Mesna, dosed asdetailed in these guidelines, is recommended to decrease the incidence ofstandard-dose ifosfamide-associated urothelial toxicity. (2) There isinsufficient evidence on which to base a guideline for the use of mesna toprevent urothelial toxicity with ifosfamide doses that exceed 2.5g/m 2/d. (3) Either mesna or forced saline diuresis isrecommended to decrease the incidence of urothelial toxicity associatedwith high-dose cyclophosphamide use in the stem-cell transplanta-tionsetting. Dexrazoxane: (1) The use of dexrazoxane is not routinelyrecommended for patients with metastatic breast cancer who receive initialdoxorubicin-based chemotherapy. (2) The use of dexrazoxane may beconsidered for patients with metastatic breast cancer who have received acumulative dosage of 300 mg/m 2 or greater of doxorubicin inthe metastatic setting and who may benefit from continueddoxorubicin-containing therapy. (3) The use of dexrazoxane in the adjuvantsetting is not recommended outside of a clinical trial. (4) The use ofdexrazoxane can be considered in adult patients who have received more than300 mg/m 2 of doxorubicin-based therapy for tumors other thanbreast cancer, although caution should be used in settings in whichdoxorubicin-based therapy has been shown to improve survival because ofconcerns of tumor protection by dexrazoxane. (5) There is insufficientevidence to make a guideline for the use of dexrazoxane in the treatment ofpediatric malignancies, with epirubicin-based regimens, or with high-doseanthracycline-containing regimens. Similarly, there is insufficientevidence on which to base a guideline for the use of dexrazoxane inpatients with cardiac risk factors or underlying cardiac disease. (6)Patients receiving dexrazoxane should continue to be monitored for cardiactoxicity. Amifostine: (1) Amifostine may be considered for the reduction ofnephrotoxicity in patients receiving cisplatin-based chemotherapy. (2)Although amifostine may be considered for the reduction of neutropenia inpatients receiving alkylating agents, chemotherapy dose reduction or growthfactor use should be considered as an alternative to the use of amifostine.(3) Present data are insufficient to recommend the use of amifostine forprotection against thrombocytopenia or the routine use of amifostine toprevent cisplatin-associated neurotoxicity or ototoxicity. Similarly,present data are insufficient to support the use of amifostine for theprevention of paclitaxel-associated neurotoxicity. (4) Use of amifostinemay be considered to decrease the incidence of acute and late xerostomia incertain patients undergoing fractionated radiation therapy in the head andneck region, although present data are insufficient to recommend the use ofamifostine to prevent radiation therapy–associated mucositis. Detailsregarding dose and management of amifostine side effects, includinghypotension, are included in the guidelines. Further research is warrantedto further define the role of these chemotherapy- andradiotherapy-protectant agents in the care of cancerpatients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Self-citationCarboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents
Sackett, D. L. (1989) · Chest · doi:10.1378/chest.95.2_supplement.2s · Cited by 1,368
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
Alexander, J., Dainiak, N., Berger, H. J., Goldman, L., Johnstone, D., Reduto, L., Duffy, T., Schwartz, P., Gottschalk, A., Zaret, B. L., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197902083000603 · Cited by 535
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy
Schwartz, R. G., McKenzie, W. B., Alexander, J., Sager, P., D'Souza, A., Manatunga, A., Schwartz, P. E., Berger, H. J., Setaro, J., Surkin, L., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90212-9 · Cited by 510
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 463
(1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2471 · Cited by 436
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.671 · Cited by 431
BRISTOW, M. R., MASON, J. W., BILLINGHAM, M. E., & DANIELS, J. R. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-2-168 · Cited by 417
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V, Hochster, H., & Meyers, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 322
Yuhas, J. M. (1980) · PubMed · Cited by 294
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Wexler, L. H., Andrich, M. P., Venzon, D., Berg, S. L., Weaver-McClure, L., Chen, C. C., Dilsizian, V, Avila, N., Jarosinski, P., Balis, F. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.362 · Cited by 224
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a · Cited by 219
TORTI, F. M., BRISTOW, M. R., HOWES, A. E., ASTON, D., STOCKDALE, F. E., CARTER, S. K., KOHLER, M., BROWN, B. W., & BILLINGHAM, M. E. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-6-745 · Cited by 215
Le Cesne, A., Antoine, E., Spielmann, M., Le Chevalier, T., Brain, E., Toussaint, C., Janin, N., Kayitalire, L., Fontaine, F., & Genin, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1600 · Cited by 207
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1957 · Cited by 197
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover, D., Glick, J. H., Weiler, C., Fox, K., & Guerry, D. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.574 · Cited by 192
Brock, N., Stekar, J., Pohl, J., Niemeyer, U., & Scheffler, G. (1979) · PubMed · Cited by 187
Dechant, K. L., Brogden, R. N., Pilkington, T., & Faulds, D. (1991) · Drugs · doi:10.2165/00003495-199142030-00006 · Cited by 182
Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
Büntzel, J., Küttner, K., Fröhlich, D., & Glatzel, M. (1998) · Annals of Oncology · doi:10.1023/a:1008282412670 · Cited by 181
Venturini, M., Michelotti, A., Del Mastro, L., Gallo, L., Carnino, F., Garrone, O., Tibaldi, C., Molea, N., Bellina, R. C., Pronzato, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.12.3112 · Cited by 165
Sorensen, K., Levitt, G., Bull, C., Chessells, J., & Sullivan, I. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.61 · Cited by 160
Increased risk of cardiac dysfunction after anthracyclines in girls
Silber, J. H., Jakacki, R. I., Larsen, R. L., Goldwein, J. W., & Barber, G. (1993) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950210704 · Cited by 151
Calabro-Jones, P. M., Aguilera, J. A., Ward, J. F., Smoluk, G. D., & Fahey, R. C. (1988) · PubMed · Cited by 149
High-dose ifosfamide with mesna uroprotection: a phase I study.
ELIAS, A. D., Eder, J. P., Shea, T., Begg, C. B., Frei, E., & Antman, K. H. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.170 · Cited by 146
López, M., Vici, P., Lauro, K. D., Conti, F., Paoletti, G., Ferraironi, A., Sciuto, R., Giannarelli, D., & MAINI, C. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.86 · Cited by 140
Use of radiation with or without WR-2721 in advanced rectal cancer
Liu, T., Liu, Y., He, S., Zhang, Z., & Kligerman, M. M. (1992) · Cancer · Cited by 133
WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
Glover, D. J., Glick, J. H., Weiler, C., Hurowitz, S., & Kligerman, M. M. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.4.584 · Cited by 124
Chemical modifiers of cancer treatment.
Coleman, C. N., Bump, E. A., & Kramer, R. A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.709 · Cited by 124
Phase I/II trials of WR-2721 and cis-platinum
Glover, D. J., Glick, J. H., Weiler, C., Fox, K. R., Turrisi, A. T., & Kligerman, M. M. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90205-1 · Cited by 112
Urological Complications of Cyclophosphamide
WATSON, N. A., & Notley, R. G. (1973) · British Journal of Urology · doi:10.1111/j.1464-410x.1973.tb12230.x · Cited by 97
Cardiac function in Wilms' tumor survivors.
Sørensen, K. E., Levitt, G., Sebag‐Montefiore, D., Bull, C., & Sullivan, I. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1546 · Cited by 95
Efficacy and cost of cardiac monitoring in patients receiving doxorubicin
Bristow, M. R., Lopez, M. B., Mason, J. W., Billingham, M. E., & Winchester, M. A. (1982) · Cancer · Cited by 92
Human pharmacokinetics of WR-2721
Shaw, L. M. J., Turrisi, A. T., Glover, D. J., Bonner, H. S., Norfleet, A. L., Weiler, C., & Kligerman, M. M. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90203-8 · Cited by 92
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
Antman, K. H., Montella, D., Rosenbaum, C., & Schwen, M. (1985) · PubMed · Cited by 87
Scheulen, M. E., Niederle, N., Bremer, K., Schütte, J., & Seeber, S. (1983) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(83)80013-9 · Cited by 85
Bennett, C. L., Weeks, J. C., Somerfield, M. R., Feinglass, J. M., & Smith, T. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3676 · Cited by 85
Taylor, C. W., Wang, L. M., List, A. F., Fernandes, D., Paine-Murrieta, G. D., Johnson, C. S., & Capizzi, R. L. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00221-9 · Cited by 56
Late cardiotoxicity after treatment for a malignant bone tumor
Postma, A., Bink‐Boelkens, M. T. E., Beaufort-Krol, G. C. M., Kengen, R. A. M., Elzenga, N. J., Leeuwen, M. J. M. S.-V., Koops, H. S., & Kamps, W. A. (1996) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199604)26:4<230::aid-mpo2>3.0.co;2-k · Cited by 54
Studies on the human pharmacokinetics of isophosphamide (NSC-109724).
Lm, A., Creaven, P. J., & Rl, N. (1976) · PubMed · Cited by 53
Decreased plasma half-life of cyclophosphamide during repeated high-dose administration
Graham, M. I., Shaw, I. C., Souhami, R. L., Sidau, B., Harper, P., & McLean, A. E. M. (1983) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00255760 · Cited by 53
Adriamycin cardiotoxicity in children.Case reports, literature review, and risk factors
Prout, M. N., Richards, M. J. S., Chung, K. J., Joo, P., & Davis, H. L. (1977) · Cancer · Cited by 52
Budd, G. T., Ganapathi, R. N., Adelstein, D. J., Pelley, R. J., Olencki, T. E., Petrus, J., McLain, D., Zhang, J., Capizzi, R. L., & Bukowski, R. M. (1997) · Cancer · Cited by 51
Randomized phase III trial of radiation±Ethyol® (Amifostine) in patients with head and neck cancer
Brizel, D. M., Sauer, R., Wannemacher, M., Henke, M., Monnier, A., Eschwège, F., Strnad, V., & Wasserman, T. H. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)80301-5 · Cited by 36
Self-citationKatz, A., Epelman, S., Anelli, A., et al. (1995) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01202226 · Cited by 33
Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas
Niederle, N., Scheulen, M. E., Cremer, M., Schütte, J., Schmidt, C. G., & Seeber, S. (1983) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(83)80018-8 · Cited by 30
Frequent Short-Term Oral Complications of Head and Neck Radiotherapy
Mossman, K. L. (1994) · Ear Nose & Throat Journal · doi:10.1177/014556139407300508 · Cited by 19
Cited by
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Radioprotectors in Radiotherapy
NAIR, C. K. K., PARIDA, D. K., & NOMURA, T. (2001) · Journal of Radiation Research · doi:10.1269/jrr.42.21 · Cited by 466
Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector
Kouvaris, J. R., Kouloulias, V. E., & Vlahos, L. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-738 · Cited by 456
Metadata
- Authors
- Hensley, M. L., Schuchter, L., Lindley, C., Meropol, N., Cohen, G., Broder, G., Gradishar, W., Green, D., Langdon, R., Mitchell, R. B., Negrin, R., Szatrowski, T., Thigpen, J. T., VonHoff, D., Wasserman, T., Winer, E., & Pfister, D.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-10
- Volume
- 17
- Issue
- 10
- Pages
- 3333-3355
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1895775305
- Cited by
- 335
- References
- 56
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.